Human FGFR2/SRE-Luc Reporter Cell Line - HEK293

The Human FGFR2/SRE-Luc Reporter Cell Line - HEK293 is an advanced in vitro assay system built on the foundational Human Embryonic Kidney 293 (HEK293) lineage. HEK293 cells are widely favored in molecular biology for their robust adherent growth, epithelial morphology, and high amenability to stable genetic engineering. This specific reporter line is genetically modified to stably overexpress the human Fibroblast Growth Factor Receptor 2 (FGFR2)—a critical receptor tyrosine kinase—alongside a stably integrated firefly luciferase (Luc) reporter gene. This reporter is under the transcriptional control of a minimal promoter containing multiple Serum Response Elements (SRE). Biologically, when a specific FGF ligand binds to the overexpressed FGFR2, it triggers receptor dimerization and autophosphorylation, which primarily activates the downstream MAPK/ERK intracellular signaling cascade. This cascade culminates in the activation of transcription factors, such as Elk-1, which directly bind to the engineered SRE promoter sequence. This binding initiates the transcription of the luciferase enzyme, resulting in a robust, quantifiable bioluminescent signal that directly correlates with the functional activation of the FGFR2 pathway.

The highly responsive nature of this engineered cell line makes it a premier tool for both fundamental signal transduction research and targeted drug discovery pipelines. In laboratory settings, the dynamic bioluminescent output provides a highly sensitive, real-time metric for quantifying FGFR2/MAPK pathway activation. This establishes an ideal platform for the high-throughput screening (HTS) and characterization of novel pharmacological agents, specifically small-molecule tyrosine kinase inhibitors (TKIs), recombinant neutralizing antibodies, and selective pathway agonists. Because aberrant FGFR2 signaling and gene fusions are fundamentally implicated in various malignancies—most notably intrahepatic cholangiocarcinoma, gastric cancer, and breast cancer—as well as severe developmental conditions like craniosynostosis syndromes, accurately monitoring its activation is critical. By enabling researchers to directly measure functional receptor signaling without relying on labor-intensive, low-throughput diagnostic assays like Western blotting for phosphorylated ERK proteins, this reporter line significantly accelerates the preclinical development and validation of FGFR-targeted therapeutics.